NL-OMON56169招募中不适用
A Phase 1 and 2a open-label trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of LAVA-1207, a PSMA-targeting bispecific γδ-T cell engager, alone or with low dose interleukin-2 or Pembrolizumab, in patients with therapy refractory metastatic castration resistant prostate cancer - LAVA1207-001
AVA Therapeutics NV0 个研究点目标入组 42 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 42
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
入选标准
- •1. Patient must be 18 years of age inclusive or above, at the time of signing
- •the informed
- •2. Male patient with mCRPC as defined by PCWG3 criteria (histologically
- •adenocarcinoma; adenocarcinoma with <=10% small-cell or neuroendocrine features
- •allowed). Brain metastases are allowed as long as the patient*s symptoms are
- •well controlled.
- •Patients is unlikely to tolerate or derive clinically meaningful benefit from
- •available therapy.
- •3. Patient should have failed at least 1 line of taxane-based chemotherapy or
- •medically unsuitable to be treated with a taxane regimen.
排除标准
- •1. Other malignancies within the last 2 years except adequately treated
- •carcinoma in situ, basal
- •or squamous cell skin carcinoma.
- •2. Uncontrolled or severe intercurrent medical condition.
- •3. Positive serological testing for human immunodeficiency virus (HIV)
研究者
相似试验
进行中（未招募）
1 期
AVA-1207 Open Label study in patients with therapy refractory metastatic castration resistant prostate cancerProstate CancerEUCTR2021-001789-39-NLAVA Therapeutics N.V.82
进行中（未招募）
1 期
AVA-1207 Open Label study in patients with therapy refractory metastatic castration resistant prostate cancerProstate CancerEUCTR2021-001789-39-ESAVA Therapeutics N.V.66
进行中（未招募）
1 期
A dose escalation trial to assess the safety and tolerability of multiple doses of the LAVA-051 antibody in patients with chronic lymphocytic leukemia, multiple myeloma or acute myeloid leukemiaCD1d-positive relapsed/refractory chronic lymphocytic leukemia (CLL), multiple myeloma (MM), or acute myeloid leukemia (AML)EUCTR2020-004583-26-ESAVA Therapeutics B.V.102
招募中
1 期
A dose escalation trial to assess the safety and tolerability of multiple doses of the LAVA-051 antibody in patients with chronic lymphocytic leukemia, multiple myeloma or acute myeloid leukemiaRelapsed/refractory chronic lymphocytic leukemia (CLL), multiple myeloma (MM), or acute myeloid leukemia (AML)EUCTR2020-004583-26-FRAVA Therapeutics B.V.102
进行中（未招募）
1 期
A dose escalation trial to assess the safety and tolerability of multiple doses of the LAVA-051 antibody in patients with chronic lymphocytic leukemia, multiple myeloma or acute myeloid leukemiaRelapsed/refractory chronic lymphocytic leukemia (CLL), multiple myeloma (MM), or acute myeloid leukemia (AML)EUCTR2020-004583-26-NLAVA Therapeutics N.V.114